The U.S. Food and Drug Administration approved a supplemental Biologics License Application for Eli Lilly and Company’s Taltz (ixekizumab) injection 80 mg/mL for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation.

Eli Lilly is planning to seek another regulatory approval for Taltz after the medication hit the primary and secondary endpoints in a Phase III study for non-radiographic axial spondyloarthritis.

The Boston Business Journal first reported that Ensemble Therapeutics has shut its doors for good. Focused on developing small molecule therapies for cancer and other disease, Ensemble Therapeutics quietly closed up shop after 13 years.

Canada’s Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N) is buying rights to AstraZeneca Plc’s (AZN.L) late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc (AMGN.O) in May.   Amgen pulled out of the project because suicidal thoughts were observed in some patients taking the medicine, casting a shadow over its prospects. Valeant said […]